Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialBo Zhang, Wenying Yang, Ping Jin et al.|Diabetes Care|2023Cited by 80
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trialYong Huo, Lei Qian, Beijian Chen et al.|The Lancet Regional Health - Western Pacific|2023Cited by 28
306-OR: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)Dalong Zhu, Lei Qian, Jiajun Zhao et al.|Diabetes|2025Cited by 2
<b>Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: A </b><b>randomized, double-blind, placebo-controlled phase 2 trial</b>Bo Zhang, Wenying Yang, Zhifeng Cheng et al.|Unknown|2023Cited by 0
<b>Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: A </b><b>randomized, double-blind, placebo-controlled phase 2 trial</b>Bo Zhang, Wenying Yang, Zhifeng Cheng et al.|Unknown|2023Cited by 0